Trial Profile
CONTINUOUS TREATMENT WITH SUNITINIB IN PATIENTS WITH SYMPTOMATIC PLEURAL AND/OR PERITONEAL MALIGNANT EFFUSIONS.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2014
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant pleural effusion; Peritoneal effusion
- Focus Therapeutic Use
- Acronyms SUPPER
- 30 Sep 2014 New trial record